Biosidus S.A.

What Biosidus S.A. does

Biosidus S.A. is an Argentine-headquartered biotechnology company founded in 1983 as a spin-off from the pharmaceutical firm Sidus, focused on the in-house development, manufacture, and global commercialization of biosimilar injectable biologics. The company operates from three integrated sites in Buenos Aires — Almagro (drug substance manufacturing and R&D laboratory), Bernal (fill-finish, lyophilization, and aseptic packaging), and Quilmes (international logistics and distribution) — and has developed nine commercial biosimilars covering erythropoietin (Hemax/Hemax LD, with 130 million cumulative doses sold), filgrastim (Neutromax, Lenobio), interferon beta (Blastoferon, Escleroferon, Bioferon), teriparatide (Osteofortil), somatropin (HHT), and a Phase III-stage agalsidase beta for Fabry disease (10th biosimilar), alongside select small molecules (azacitidine, bortezomib, fingolimod, buprenorphine). Its proprietary platform combines mammalian cell culture, bacterial fermentation, aseptic fill-finish, and an innovative transgenic cow biomanufacturing approach, supported by an in-house R&D team of approximately 17 PhD scientists.

The business model is B2B institutional: Biosidus sells through government tenders, hospital procurement, and public health systems in emerging markets (Latin America, Africa, Middle East, Asia, Eastern Europe), with pricing negotiated at institutional level and biosimilars priced 15-30% below originator biologics. Revenue is generated through direct sales via regional offices (Bogotá, Mexico City, Dubai, Bangkok, Barcelona) and through channel partners including Sandoz (Argentina distribution), Mubadala Bio (UAE, DiabTec platform), and tech-transfer/local-production partners in Algeria (>50% market share in certain segments) and Brazil. The company holds 300+ marketing authorizations and intentionally does not compete in the US, Canada, Western Europe, or Japan. Leadership is led by President & CEO Mariano de Elizalde, with a 7-member board, ~500 employees, and no disclosed external equity backers beyond a 2018 debt/structured round.

Name

Biosidus S.A.

Legal name

Biosidus S.A.

Website

https://biosidus.com.ar

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Biosidus S.A. is an Argentine-headquartered biotechnology company developing, manufacturing, and distributing nine biosimilars and select small molecules for chronic and rare diseases across 60+ emerging market countries.

Ownership category

akta.pro rank

Product category

Biosimilar Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biosimilar Manufacturing & Fill-Finish (drug substance/drug product, device integration) (HLAAAHAK)

akta.pro secondary industries

Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution) (HLAAAHAL), Biologics & Biosimilars Distributors (HLAIAJAH), Other Recombinant Protein Biosimilars (non-mAb, non-hormone) (HLAIAFAL)

Keywords

• Biosimilar pharmaceuticals
• Biological drug manufacturing
• Erythropoietin biosimilars
• Oncology biosimilars
• Biopharmaceutical distribution

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Proprietary Biosimilar Product Sales: Biosidus develops, manufactures, and commercializes its own portfolio of nine biosimilars. Revenue is generated through direct sales to healthcare systems, hospitals, pharmacies, and government procurement tenders across emerging markets in Latin America, Africa, Asia, and Eastern Europe.
2. Distribution Licensing with Large Pharma Companies: Biosidus signs licensing and distribution agreements with large pharmaceutical companies (e.g., Sandoz) for supplemental biologics. Biosidus supplies or licenses products while partners handle local commercialization and distribution, providing additional revenue streams and market access.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Biosidus is an Argentine biotechnology company that develops, manufactures, and commercializes a portfolio of nine biosimilars and several small molecule pharmaceuticals. The biosimilar portfolio covers erythropoietin, filgrastim, lenograstim, somatropin, teriparatide, interferon beta, and agalsidase beta, treating chronic kidney disease, multiple sclerosis, cancer, growth disorders, and rare lysosomal storage disorders. The company operates fully integrated manufacturing in Argentina (drug substance, fill-finish, and logistics) and distributes through direct sales offices, joint ventures, and licensing partners across more than 60 emerging markets in Latin America, Africa, the Middle East, Asia, and Eastern Europe.

Product overview

Biosidus is a biotechnology company headquartered in Argentina that develops and commercializes a portfolio of 9 biosimilars and small molecule pharmaceuticals. The biosimilar portfolio includes erythropoietin products (Hemax and Hemax LD), filgrastim products (Neutromax and Lenobio), interferon beta products (Blastoferon, Escleroferon, and Bioferon), teriparatide (Osteofortil), and growth hormone (HHT). The small molecule portfolio includes azacitidine (Amilix), bortezomib (Bromadene), fingolimod (Biomonar), and buprenorphine (Restiva). The company operates integrated manufacturing facilities in Buenos Aires, Argentina, and distributes products to over 60 countries worldwide through a network of sales offices, joint ventures, and strategic partnerships.

Differentiator

Problem solved

Functional benefit

Brands

• Hemax: Erythropoietin (EPO) biosimilar for treating anemia associated with chronic kidney disease. Available in multiple formulations including lyophilized powder (LD) and higher doses.
• Neutromax
• Lenobio
• Osteofortil
• HHT
• Blastoferon
• Escleroferon
• Bioferon
• Bromadene
• Amilix
• Biomonar
• Restiva
• Agalzyme
• BioesVida

Products and services

• Hemax (Erythropoietin) Erythropoietin biosimilar available in high-dose formulations (10K, 20K, 40K U.I.) for treating anemia associated with chronic kidney disease.
• Hemax LD First lyophilized erythropoietin formulation that does not require cold chain storage. Available in low-dose formulations (1000-4000 U.I.) with over 130 million doses sold worldwide.
• Neutromax Filgrastim biosimilar (rHuG-CSF) with 60% market presence in Argentina and leadership position in Brazil. Used for prevention of febrile neutropenia in chemotherapy patients.
• Lenobio Glycosylated recombinant human granulocyte colony-stimulating factor (rHuG-CSF) for prevention of febrile neutropenia and mobilization of peripheral blood stem cells.
• Osteofortil First teriparatide biosimilar with a comparative clinical trial of efficacy and safety versus innovator. Pre-filled syringes containing 20 mcg teriparatide for osteoporosis treatment.
• HHT (Somatropin) Somatropin (human growth hormone) biosimilar available in lyophilized powder formulations (4 UI and 16 UI). Used for growth hormone deficiency in children with over 20 years of clinical experience.
• Blastoferon Interferon beta 1a biosimilar (European standard) launched in Argentina in 2005. Pre-filled syringes with 22 mcg or 44 mcg doses for treating relapsing remitting multiple sclerosis.
• Escleroferon Interferon beta 1a biosimilar with once-weekly dosing. Pre-filled syringes containing 30 mcg for multiple sclerosis treatment.
• Bioferon Interferon biosimilar with broad-spectrum antiviral properties. Available in 3, 5, and 10 mIU vial formulations for reconstitution.
• Agalzyme Agalsidase beta biosimilar for the treatment of Fabry disease. Available in 5 mg and 35 mg vials for intravenous infusion.
• Amilix Azacitidine small molecule drug for adult patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia who are not eligible for hematopoietic stem cell transplantation.
• Bromadene Bortezomib small molecule for front-line treatment of symptomatic multiple myeloma patients. Supplied as 3.5 mg sterile lyophilized powder for reconstitution.
• Biomonar Fingolimod small molecule - first orally administered treatment for active relapsing remitting multiple sclerosis with over 10 years of real-life experience.
• Restiva Buprenorphine transdermal patches for treatment of moderate to severe pain not responsive to non-opioid analgesics. Available in 5, 10, and 20 mg doses.

Quantifiable outcome

• 130 million doses sold globally since launch for Hemax erythropoietin biosimilar
• +5 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core.

• Mubadala BiocoreChannel Partner/ Reseller/ Distributor · 24 June 2026Biosidus signed a licensing and supply agreement with Mubadala Bio to introduce a portfolio of biologic therapies in the UAE through Mubadala Bio's biologics platform DiabTec. The agreement was signed at BIO International Convention 2026 and witnessed by Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi. The collaboration covers therapies across endocrinology, nephrology, and oncology including epoetin alfa, filgrastim, interferon beta, and somatropin.
• SandozcoreChannel Partner/ Reseller/ DistributorSandoz signed an agreement with Biosidus for the commercialization and distribution of current products and future launches in Argentina. This partnership extends Biosidus's market reach within Argentina through Sandoz's established pharmaceutical distribution network.
• Brazil Partner (Local Production)coreStrategic or Co-development PartnerPartnership in Brazil enabling local production and distribution of Biosidus biosimilars, greatly enhancing market presence in one of Latin America's largest pharmaceutical markets.
• Algeria Partner (Packaging & Distribution)coreChannel Partner/ Reseller/ DistributorCollaboration in Algeria for packaging and distribution of Biosidus biosimilars. This partnership established Biosidus as a dominant player with over 50% market share in certain segments in Algeria. The new facility in Algeria handles packaging initially and will eventually move toward full local production.

Scale indicators12 records

Recent moves11 records

Expansion highlights8 records

Broad incumbents

• Sandoz (Novartis): Global biosimilar and generics leader with a deep biosimilar portfolio across oncology, immunology and endocrinology. Comparable as a biosimilar incumbent and Biosidus's distribution partner in Argentina, but with vastly broader molecule coverage and global reach.
• Teva Pharmaceutical Industries: Global generics and specialty pharma company with biosimilars (rituximab, trastuzumab) and broad emerging-market presence. Comparable on the biosimilar plus generics hybrid model and emerging-market distribution.
• Amgen: Global biopharmaceutical originator that has both developed originator biologics and a growing biosimilar portfolio (e.g., adalimumab, bevacizumab, trastuzumab). Comparable as a major player in both originator biologics and biosimilars, with manufacturing scale Biosidus aspires to.

Direct peers

• Celltrion: South Korea-headquartered biosimilar pioneer, leading global supplier of infliximab, rituximab, trastuzumab and adalimumab biosimilars. Directly comparable to Biosidus as a vertically integrated biosimilar developer with strong emerging-market commercial footprint.
• Samsung Bioepis: Joint venture between Samsung Biologics and Biogen developing biosimilars in oncology, immunology and ophthalmology (etanercept, infliximab, adalimumab, trastuzumab, ranibizumab). Comparable as a focused biosimilar developer competing on cost and quality in regulated and emerging markets.
• Dr. Reddy's Laboratories: Indian generics and biosimilar company with biosimilars in oncology (rituximab, bevacizumab, pegfilgrastim) and a strong emerging-market commercial network. Comparable to Biosidus on biosimilar pipeline and emerging-market distribution model.
• mAbxience: Argentina-headquartered biosimilar developer (part of Insud Pharma group) producing monoclonal antibody biosimilars for global markets. The closest geographic and business-model peer to Biosidus — Argentine biosimilar company with international commercialization.
• Biocon: India-based global biosimilar manufacturer with a portfolio covering insulin, trastuzumab, bevacizumab, pegfilgrastim and other recombinant biologics. Comparable to Biosidus as a focused biosimilar developer serving price-sensitive markets, though at much larger scale and broader molecule coverage.

Emerging players

• Shanghai Henlius Biotech: Chinese biosimilar developer with approvals in China, Europe and emerging markets (rituximab, trastuzumab, adalimumab, bevacizumab). Comparable as a newer biosimilar entrant expanding into Latin America, Africa and Asia with cost-competitive biologics.
• Hetero Drugs: Indian generics and biosimilar manufacturer with biosimilars in oncology (rituximab, bevacizumab) and a strong public-procurement track record in emerging markets. Comparable to Biosidus on cost-competitive biosimilars for tender-driven healthcare systems.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInar.linkedin.com/company/bio-sidus

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosidus S.A.